GLOW and KLOW compared: what is in each research blend
Research Blends
Research Peptide Learning Centre · Published 7 October 2026 · 5 min read
GLOW and KLOW side by side: what each research blend contains, the single component that separates them, how the components are studied, and the records to check.
GLOW and KLOW are research blends built on the same base of three peptides, with one addition that distinguishes them. This guide sets them next to each other, summarises what each component has been studied for, and explains how to compare blends without over-reading a product page. It is educational and is not a route to personal use or a determination that any activity is permitted.
What is in each blend
The listings state GLOW at 70 mg per vial (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg) and KLOW at 80 mg per vial (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg). The single difference is KPV: KLOW is GLOW plus the KPV tripeptide. A blend combines separately studied materials in one vial; it does not create a third compound with its own validated effect, and no combined pharmacology or purity is claimed for either.
The three shared components
GHK-Cu is the copper tripeptide, studied in skin-remodelling and gene-expression research; a review summarises its reported actions and the gene data behind them (Pickart & Margolina, 2018). See the GHK-Cu research profile and the GHK-Cu research guide. BPC-157 is a 15-amino-acid peptide examined in tendon-cell and tissue-response models, with defined cell endpoints rather than proven injury repair (Chang et al., 2011). TB-500 is Thymosin beta-4, a 43-amino-acid actin-binding peptide studied in cell-migration and repair models (Goldstein et al., 2005).
The KPV difference
KPV is the lysine-proline-valine tripeptide, a C-terminal fragment of alpha-melanocyte-stimulating hormone. It has been studied in anti-inflammatory models; one study reported that the tripeptide, taken up through the PepT1 transporter, reduced intestinal inflammation in murine colitis models (Dalmasso et al., 2008). As with the other components, this describes a research model, not a demonstrated effect of the blend in people.
Reading the milligram totals
The 70 mg and 80 mg figures are the sum of the stated component amounts, not a grade or a quality score. KLOW’s higher total is simply GLOW’s three components plus 10 mg of KPV; it does not make KLOW “stronger” in any validated sense, because the two blends are built for different research interests rather than ranked on a single scale. The amount that matters for a given method is the specific component being examined, not the vial’s total. The guide to lyophilised peptides covers how a multi-component vial of this kind is kept and reconstituted once its contents are confirmed.
Comparing two blends responsibly
When two blends look similar, the useful question is not which number is larger but whether each component’s identity and documentation are accounted for. Record the stated composition, match any report to the proposed lot, and keep analytical suitability separate from commercial terms. A batch-specific certificate of analysis is not yet published for GLOW or KLOW, and no purity percentage is claimed for either. A research-use label does not settle regulatory questions; Health Canada’s advisory on online injectable peptides states that research-use wording does not exempt products from regulatory requirements. Read the advisory. The COA guide and the Certificate Library cover the analytical side.
Common questions
What is the difference between GLOW and KLOW?
KLOW is GLOW plus KPV. GLOW contains GHK-Cu, BPC-157 and TB-500 (70 mg); KLOW adds KPV for 80 mg.
Do GLOW and KLOW have certificates of analysis?
A batch-specific certificate is not yet published for either blend, and no purity percentage is claimed. When one is released, it will be connected to the corresponding lot.
What is KPV?
KPV is the lysine-proline-valine tripeptide, a fragment of alpha-MSH, studied in anti-inflammatory research models.
Is KLOW stronger than GLOW because it is 80 mg?
No. The total is the sum of the stated component amounts. KLOW is GLOW plus 10 mg of KPV; the figure is not a grade, and the amount that matters for a method is the specific component, not the vial total.
Are GLOW and KLOW intended for human use?
No. They are presented for laboratory and analytical research only, and this guide is not a treatment or personal-use protocol.
Sources and scope
- Pickart & Margolina, 2018 — Regenerative and protective actions of the GHK-Cu peptide (Int J Mol Sci)
- Chang et al., 2011 — BPC-157 and tendon healing (J Appl Physiol)
- Goldstein et al., 2005 — Thymosin beta4 (Trends Mol Med)
- Dalmasso et al., 2008 — PepT1-mediated tripeptide KPV reduces intestinal inflammation (Gastroenterology)
- Health Canada: advisory on unauthorized injectable peptides
Published research describes the material and conditions used by its authors. It does not test, certify or endorse Reforge inventory. This guide is educational and is not a treatment or personal-use protocol.